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Abstract
Summary On the basis of updated fracture and mortality
data, we recommend that the base population values used in
the US version of FRAX® be revised. The impact of
suggested changes is likely to be a lowering of 10-year
fracture probabilities.
Introduction EvaluationofresultsproducedbytheUSversion
of FRAX® indicates that this tool overestimates the likelihood
of major osteoporotic fracture. In an attempt to correct this, we
updated underlying fracture and mortality rates for the model.
Methods We used US hospital discharge data from 2006 to
calculate annual age- and sex-specific hip fracture rates and
age-specific ratios to estimate clinical vertebral fracture
rates. To estimate the incidence of any one of four major
osteoporotic fractures, we first summed these newly derived
hip and vertebral fracture estimates with Olmsted County,
MN, wrist and upper humerus fracture rates, and then
applied 10–20% discounts for overlap.
Results Compared with rates used in the current FRAX®
tool, 2006 hip fracture rates are about 16% lower, with
greatest reductions observed among those below age
65 years; major osteoporotic fracture rates are about one
quarter lower, with similar reductions across all ages.
Conclusions We recommend revising the US-FRAX by
updating current base population values for hip fracture and
major osteoporotic fracture. The impact of these revisions
on FRAX® is likely to be lowering of 10-year fracture
probabilities, but more precise estimates of the impact of
these changes will be available after these new rates are
incorporated into the FRAX® tool.
Keywords Fracture.FRAX®.Riskassessment
Introduction
Growth of the elderly population will lead to dramatic
increasesin osteoporosis-related fractures in coming decades
[1]. Currently, an estimated 10 million Americans ≥50 years
old have osteoporosis according to World Health Organi-
zation (WHO) criteria [2], while over 33 million more have
“osteopenia” (analogous to “prediabetes”); the total number
with low bone mass could reach 61 million by 2020 [3].
Consequently, the estimated 2 million osteoporosis-related
fractures in 2005 could exceed 3 million by 2025, with an
associated increase in cost from $16.9 billion to $25.3 billion
annually [4]. To significantly reduce future fractures,
interventions must be broadly applied because most of the
population is at some degree of risk. However, public health
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or cost-effectiveness [7] and may have unexpected adverse
outcomes [8]. Pharmacologic prophylaxis is efficacious
[9] but has significant side effects [10–12], and in
addition, treating the entire community is unaffordable.
The key is to discriminate the patients at sufficiently
high fracture risk from those at lower risk in whom
expensive osteoporosis interventions will have limited
value. In the past, risk stratification has relied primarily
on bone densitometry, which is both insensitive and
nonspecific for fracture outcomes [13–16]; however, sensi-
tivity and specificity can be improved simultaneously by
increasing the assessment gradient of risk [17]. This is
accomplished in the WHO’s new fracture prediction
algorithm, FRAX®, by augmenting bone mineral density
(BMD) data with documentation of clinical risk factors in
order to predict a patient’s 10-year fracture probability [18].
FRAX® now provides the basis for the National Osteopo-
rosis Foundation’s (NOF) individualized approach to
fracture prevention [19]. It is important for prediction of
the fracture probability to be as accurate as possible, and
recently, the opportunity has presented itself to improve the
data used to calculate a patient’s fracture risk in the US
version of the FRAX® tool (US-FRAX). This report
explains the rationale for these revisions and estimates
their impact on results obtained with the fracture tool.
US-FRAX 10-year hip fracture probability
Since fracture incidence varies by age, sex, race, and
geographic region [20], the FRAX® algorithm must be
calibrated to each population using local hip fracture and
mortality rates. In the case of the USA, the model was
calibrated to data on hip fracture incidence from Olmsted
County, MN, combined with national death rates.
Hip fracture incidence rates—non-Hispanic whites
In lieu of better data at the time, both the original version of
the US-FRAX posted February 2008 and the revision
posted October 2008 (www.sheffield.ac.uk/FRAX) were
calibrated to hip fracture incidence rates documented for the
predominantly white population of Olmsted County during
1989–1991 [21]. Comparably age- and sex-adjusted to the
2000 US white population, the 1989–1991 Olmsted County
annual incidence rate for those age 50 years and older was
3.86 per 1,000, quite similar to the 3.91 per 1,000 figure
later reported for US whites for the year 2001 [4]. Using
these rates, the US-FRAX reports 10-year hip fracture
probability estimates similar to those reported for several
European countries. However, the Olmsted County rates
were based on relatively small numbers of fracture cases,
and these 1989–1991 data are now outdated given evidence
that hip fracture incidence rates are declining in the white
population of this country [22–25].
In order to obtain more recent and robust data, we
updated these hip fracture rates using 2006 hospital
discharge data for non-Hispanic white women and men
from the Healthcare Cost and Utilization Project (HCUP)
Nationwide Inpatient Sample (NIS) that was previously
used by Burge et al. [4] to estimate national hip fracture
incidence rates for the white population in 2001. The NIS is
a random sampling of 20% of hospital discharges each year.
This data set is created by the Agency for Health Care
Research and Quality through HCUP and calculates
weightings that allow discharge rates to be up-weighted to
project rates for the entire US population. The most recent
data available to us were for 2006 and include reporting
from 38 states. As in previous analyses [4], proximal femur
fractures were defined as ICD-9-CM codes 820.0× (trans-
cervical), 820.2× (pertrochanteric), and 820.8× (neck of
femur). To be conservative, open fractures were excluded.
Moreover, only cases with a primary diagnosis of fracture
were included: Any patients with only secondary fracture
diagnoses were excluded, as were hospital admissions due
to severe trauma (based on E-codes; less than 2% of the
total). Although ten states reported little or no information
on race, 24 of the 38 states in 2006 NIS had acceptable or
near-complete race reporting, with 0–8% of hip fracture
subjects missing race (most 1–2%); four other states had
16–42% missing race data. Based on race reporting from
these 28 states, we derived an equation that predicted the
percentage of each state’s hip fractures that occurred among
whites from the percentage of the white population in that
state. The contribution of each state to the equation was
weighted by its number of hip fractures. Next, we applied the
weighted equation to all hip fractures missing race (about
one quarter of the total). We then obtained US Census
projections for 2006 and collected denominator numbers of
non-Hispanic whites by sex and age; hip fracture incidence
rates for this population were then estimated by 5-year age
groups. All programming was done using the NIS-specific
macros and the SAS programming language (SAS 9.1, SAS
Institute, Cary, NC). A smoothing function from Proc
REGLIN in SAS was then applied to the 5-year incidence
rates to smooth the data and create single-year of age
incidence rates to be used in the US-FRAX algorithm.
The resulting hip fracture incidence rates are shown in
Table 1 and in Fig. 1a and b for men and women,
respectively. Although overall age- and sex-adjusted rates
were similar between Olmsted County in 1989–1991 and
NIS in 2006, only 19 hip fracture cases were available to
estimate the Olmsted County rates for women age 50–
64 years, and only nine cases for men in this age group.
Using 2006 NIS data, these estimates were based on several
26 Osteoporos Int (2010) 21:25–33thousand events in women and men in these age groups.
These vastly larger numbers suggest that the revised
estimates will be much more reliable, especially among
younger men and women. The 2006 NIS rates for the oldest
age group are somewhat greater than the Olmsted County
figures, but this likely reflects a shift to older average ages
within the 85+ age group due to secular demographic
changes in the underlying population [26]. Finally, the more
recent overall 2006 NIS rates are 16% lower than compara-
bly age- and sex-adjusted NIS rates from 2001 (4.31 per
1,000), reflecting the ongoing decline in hip fracture
incidence observed nationally [22–25]. US-FRAX will use
the 1-year age intervals for hip fracture, a significant
improvement in accuracy over the previous 5-year age data
(John Kanis, May 11, 2009, personal communication). The
major impact of the change in base hip fracture incidence
will be among younger women and men, where hip fracture
probability estimates could be up to 40% lower than those
currently produced by US-FRAX.
US-FRAX 10-year major osteoporotic fracture
probability
Because hip fractures represent the minority of osteoporotic
fractures [29], a focus on hip fractures alone could be
misleading for high-risk younger individuals whose 10-year
risk relates more to spine and wrist fractures. Consequently,
FRAX® also estimates the patient’s 10-year likelihood of
any one of four major osteoporotic fractures (4 fracture risk:
proximal femur, clinical vertebral, distal radius, or proximal
humerus fractures), and some revisions in those calcula-
tions were indicated as well.
Fracture site-specific incidence rates
In its current implementation, US-FRAX also used 1989–
1991 Olmsted County data for fracture-specific incidence
rates [21] and produced age- and sex-specific incidence
rates for four fractures by considering them all together and
modeling the risk of any one [30] (Table 2). Unlike the US-
FRAX 10-year hip fracture probabilities, which seem
consistent with FRAX® estimates from other countries as
well as US cohort studies, the 4-fracture 10-year probabil-
ities produced by US-FRAX are higher than those in other
countries and higher than those observed in the Study of
Osteoporotic Fractures (SOF; Meghan G. Donaldson,
personal communication). Moreover, the ratio of the 10-
year 4 fracture and hip fracture probability alone was much
greater than seen elsewhere. For example, in the current
version of US-FRAX, the 4 fracture and hip fracture ratio in
65-year-old women is 11:1, whereas it is only about 6:1 in
Age-group Olmsted County, MN, 1989–1991 [21] National Inpatient Sample, 2006
Rate No. of fractures Rate No. of fractures
Women
50–54 0.66 5 0.29 2,197
55–59 0.83 5 0.57 3,992
60–64 1.65 9 1.05 5,679
65–69 2.21 11 2.03 8,690
70–74 2.75 12 3.94 14,578
75–79 8.61 33 7.93 27,488
80-84 18.38 57 14.47 42,322
85+ 24.88 85 26.05 82,383
Subtotal 5.37
a 217 4.97
a 187,339
Men
50–54 0.40 3 0.28 2,062
55–59 0.32 2 0.38 2,528
60–64 0.81 4 0.66 3,333
65–69 1.89 8 1.18 4,510
70–74 1.60 5 2.10 6,462
75–79 5.34 12 4.02 10,355
80–84 5.97 8 8.13 14,724
85+ 15.01 16 16.30 23,060
Subtotal 2.10
a 58 2.09
a 67,034
Total 3.86
b 275 3.64
b 254,373
Table 1 Estimated
annual hip fracture incidence
(per 1,000) comparing current
and revised rates
aIncidence per 1,000 directly
age-adjusted to the 2006 US
non-Hispanic white population
bIncidenceper1,000directlyage-
and sex-adjusted to the 2006 US
non-Hispanic white population
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6.6 in the UK [31].
In order to clarify this discrepancy, a review of the data
currently used for the US-FRAX implementation was
conducted. The incidence data were compared to cohort
studies in the USA and elsewhere and specifically
compared to 4 fracture assumptions used in the implemen-
tation of FRAX® in other countries. Upon closer inspec-
tion, it was determined that the incidence rates for forearm
and humerus fractures from Olmsted County were similar
to those seen in other studies, and the overall discrepancy in
10-year 4 fracture probabilities could be attributed primarily
to the high incidence of vertebral fractures reported for
Olmsted County residents compared to other settings
(Table 3). In the Olmsted County analysis, these all were
“clinical” vertebral fractures insofar as they were recog-
nized in the course of routine care by the providers of
inpatient and outpatient medical care in the community, and
all were confirmed on a contemporary radiologist’s report
[21]. Although the fractures represented discrete events,
they were not necessarily first-ever vertebral fractures.
Thus, the overall age- and sex-adjusted (to the 2000 US
white population) annual incidence of vertebral fractures in
Olmsted County was 4.39 per 1,000, but this was reduced
to 3.89 per 1,000 if only initial vertebral fractures in 1989–
1991 were counted. If, however, only first-ever (in a
lifetime) vertebral fractures were considered, the incidence
rate would be just 1.41 per 1,000 based on community data
for 1985–1994 [32]. More importantly, many vertebral
fractures in the Olmsted County analysis were diagnosed
incidentally, as they came to attention while working up
some other problem, including other osteoporotic fractures
(one patient in ten in the 1989–1991 study) as seen also by
others [33]; clearly, these do not all reflect “symptomatic”
vertebral fractures, i.e., painful back prompting radiograph
with fracture reading confirmed.
After extensive discussions, it was concluded that there
was a need to revise the vertebral fracture incidence rates
used in the US-FRAX. Unfortunately, every potential
alternative source of data also has important limitations,
including restrictions by age and sex or reliance of
examinations of study volunteers in cohort studies. More-
over, the lack of a uniform definition and the problem of
distinguishing incident from prevalent vertebral fractures
are major stumbling blocks [34]. The solution was derived
from the previous work of Kanis et al. [30], who used the
ratio of clinical vertebral fractures to hip fractures from
Malmo, Sweden to estimate clinical vertebral fracture rates
for women in the UK implementation of FRAX® [31]. We
replicated this process and replaced the Olmsted County
vertebral fracture rates with estimates based on the ratio of
clinical vertebral to hip fracture incidence in the Malmo
data, which were then applied to the revised hip fracture
rates from the NIS data (see above). As shown in Table 4,
this resulted in estimated clinical (~symptomatic) vertebral
fracture rates much lower than those US-FRAX employed
from Olmsted County.
Overlap among fracture types
To obtain a more accurate estimate of annual risk for any of
the four fractures, it would be of interest to adjust for
multiple counting inherent in summing the annual risks for
the four individual types of fractures. Adjusting for multiple
counting would have decreased the overall Olmsted County
rates by 16% (difference between reported fracture counts
and numbers of people with any fracture) [21]. In order to
accurately adjust for this overlap, it would be ideal to have
population data showing the annual age- and sex-specific
incidence for each of the four fracture types separately as
well as rates for any one of the four in any one individual.
This would allow creation of an age- and sex-specific
“discount” to the sum of the 4 fracture rates. An age-
specific discount would be ideal, as the overlap is likely to
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Fig. 1 a, b Comparison of hip fracture incidence rates ( ) to the
incidence of any one of four (hip, spine, forearm, or humerus) major
osteoporotic fractures ( ) among non-Hispanic white men (a) and
non-Hispanic white women (b) by single year of age (smoothed data)
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increases. However, there is no perfect source of such data
in the USA to estimate this discount. From Malmo, Kanis et
al. [30] present 10-year rates of each of the four fractures as
well as the 10-year modeled rate of “any one of the four.”
This data set included both men and women in 5-year age
groups 45 years and older and has served in the past as the
FRAX® adjustment for overlap (John Kanis, March 2,
2009, personal communication). A second source to verify
this adjustment has been provided by the SOF, a cohort
study of US women over age 65 years. Utilizing the SOF
data, we were able to perform an analysis comparing the
10-year incidence rates of each of the four fracture types to
the 10-year incidence of any one of the four and thus were
able to calculate a discount rate, albeit only for older
women. Comparing the two results, we derived the
discount percentages shown in Table 5. For Malmo data,
the ratio of the incidence of any of the four to the sum of
the four varies from 0.87 (13% over counting using the
“sum”) in age group 50–54 to 0.74 (26% over counting) in
age group 75–79 years. The Malmo estimates are based on
statistical models, but the empirical comparison of annual
risk from SOF (Table 5) shows similar “discounts” for over
counting of 9–18% among women over age 65 years.
Based on these two data sources, in order to estimate the
annual risk for any of the four fractures that is adjusted for
overlap, the sum of the four should be discounted by 10%
Table 2 Comparison of current (Olmsted County, MN) and revised fracture rates (annual incidence per 1,000), along with revised incidence
ratios of any one of four major osteoporotic fracture to hip fracture
Age
group
Hip Vertebra Humerus Forearm Incidence of major
osteoporotic
fractures
Ratio of 4 fracture
to hip fracture
alone
Current [21] Revised Current [21] Revised Current [21] Revised Current [21] Revised Current
a Revised
b Current
a Revised
b
Women
50–54 0.66 0.29 2.25 0.64 0.66 0.66 2.91 2.91 5.83 4.05 8.83 13.97
55–59 0.83 0.57 2.15 1.32 1.65 1.65 4.30 4.30 8.04 7.06 9.69 12.39
60–64 1.65 1.05 3.49 1.24 1.65 1.65 8.08 8.08 13.38 10.82 8.11 10.30
65–69 2.21 2.03 6.82 2.33 1.40 1.40 8.22 8.22 15.85 11.88 7.17 5.85
70–74 2.75 3.94 11.67 4.73 3.43 3.43 8.24 8.24 22.18 17.29 8.07 4.39
75–79 8.61 7.93 15.66 5.23 2.44 2.44 8.35 8.35 28.05 19.16 3.26 2.42
80–84 18.38 14.47 25.79 6.22 5.48 5.48 8.70 8.70 46.68 27.90 2.54 1.93
85+ 24.88 26.06 31.32 10.95 4.98 4.98 8.49 8.49 55.74 40.38 2.24 1.55
Men
50–54 0.40 0.28 0.94 0.43 0.27 0.27 1.47 1.47 2.77 2.21 6.93 7.89
55–59 0.32 0.38 1.60 0.46 0.48 0.48 0.64 0.64 2.74 1.76 8.56 4.63
60–64 0.81 0.66 0.81 1.78 0.81 0.81 1.41 1.41 3.46 4.19 4.27 6.35
65–69 1.89 1.18 4.97 1.14 1.42 1.42 0.95 0.95 7.85 3.99 4.15 3.38
70–74 1.60 2.10 4.15 2.14 1.60 1.60 0.64 0.64 6.79 5.51 4.24 2.62
75–79 5.34 4.02 6.68 3.50 1.34 1.34 0.45 0.45 11.74 7.45 2.20 1.85
80–84 5.97 8.13 15.67 3.58 0.75 0.75 1.49 1.49 19.10 11.16 3.20 1.37
85+ 15.01 16.30 25.33 12.39 1.88 1.88 0.94 0.94 34.53 25.21 2.30 1.55
aThe risk of any one of four major osteoporotic fractures (proximal femur, clinical vertebral, proximal humerus, and distal radius) calculated from
the sum of risks for 4 individual fracture types, from Olmstead County, MN [21], after overlap discount applied (see text)
bThe sum of revised risks of any one of four major osteoporotic fractures, after overlap discount applied (see text)
Table 3 Comparison of annual incidence (per 1,000) of “clinical”
spine fractures in women from several studies
Age group Olmsted County, MN [21] Malmo, Sweden [32] SOF
a
50–54 2.25 1.17 –
55–59 2.15 1.27 –
60–64 3.49 2.12 –
65–69 6.82 3.29 2.73
70–74 11.67 5.83 2.61
75–79 15.66 7.61 3.31
80–84 25.79 7.70 5.61
85–89 31.32 12.63 4.36
Note that each study defines clinical vertebral fractures differently and
that the data from Malmo, Sweden and the Study of Osteoporotic
Fractures (SOF) relate to symptomatic vertebral fractures only, i.e.,
painful back prompting radiograph with fracture reading confirmed
aUnpublished data
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age 75 years and over. We applied this discount to derive
annual 4 fracture incidence rates (both for current and
revised incidence sums), which are delineated in Table 2
and Fig. 1a and b.
Mortality rates
The FRAX® model also requires age-specific mortality
rates. Mortality data are important because the risk of
death competes with the risk of fracture. Increased life
Table 4 Annual incidence of clinical vertebral and hip fractures (per 1,000) and their ratios in Malmo, Sweden, applied to the National Inpatient
Sample (NIS) 2006 hip fracture rates, to estimate the annual incidence of clinical vertebral fractures (per 1,000) in the US
Age group Malmo [32] US-FRAX
Vertebral fracture
incidence
÷ Hip fracture
incidence
= Vertebral/hip
fracture ratio
NIS 2006 hip
fracture incidence
Estimated vertebral
fracture incidence
a
Women
50–54 1.17 0.53 2.21 0.29 0.64
55–59 1.27 0.55 2.31 0.57 1.32
60–64 2.12 1.80 1.18 1.05 1.24
65–69 3.29 2.86 1.15 2.03 2.33
70–74 5.83 4.86 1.20 3.94 4.73
75–79 7.61 11.51 0.66 7.93 5.23
80–84 7.70 17.99 0.43 14.47 6.22
85–89 12.63 29.73 0.42 26.06 10.95
Men
50–54 1.35 0.87 1.55 0.28 0.43
55–59 1.02 0.85 1.20 0.38 0.46
60–64 1.91 0.71 2.69 0.66 1.78
65–69 1.73 1.78 0.97 1.18 1.14
70–74 2.85 2.80 1.02 2.10 2.14
75–79 4.95 5.68 0.87 4.02 3.50
80–84 5.60 12.67 0.44 8.13 3.58
85–89 11.08 14.49 0.76 16.30 12.39
aProduct of vertebral/hip fracture ratio times NIS 2006 hip fracture incidence
Table 5 Comparison of results obtained from calculating risk of any one of four major osteoporotic fractures among postmenopausal white
women by either summing rates of four individual types of fracture or by measuring the risk of any one of the four types, comparing data from
Malmo, Sweden, with prospective data from the Study of Osteoporotic Fractures (SOF)
Malmo 10-year risk [32] SOF 10-year risk
a
Age Any of 4 Sum of 4 Ratio of “any” to sum
(and implied discount to sum)
Age Any of 4 Sum of 4 Ratio of “any” to sum
(and implied discount to sum)
50 6.0 6.9 0.87 (13%)
55 7.8 9.0 0.87 (13%)
60 10.6 12.9 0.82 (18%)
65 14.3 18.1 0.79 (21%) 65–69 12.9 14.29 0.91 (9%)
70 18.9 24.8 0.76 (24%) 70–74 17.3 20.13 0.86 (14%)
75 22.9 30.8 0.74 (26%) 75–79 24.24 27.54 0.88 (12%)
80 26.5 35.3 0.75 (25%) 80–84 26.45 32.16 0.82 (18%)
85 27.0 35.2 0.77 (24%) ≥85 34.53 38.74 0.89 (11%)
90 21.4 27.5 0.78 (22%)
Discount is the estimated decrease in the sum of the four due to overlap in individuals suffering more than one type of fracture
aStudy of Osteoporotic Fractures: unpublished data
Table 5 Comparison of results obtained from calculating risk of any
one of four major osteoporotic fractures among postmenopausal white
women by either summing rates of four individual types of fracture or
by measuring the risk of any one of the four types, comparing data
from Malmo, Sweden, with prospective data from the Study of
Osteoporotic Fractures (SOF)
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death rates would have the effect of increasing estimated
10-year fracture likelihood, particularly among older age
groups. US-FRAX used age-, sex-, and race-specific
death rates for the US population in 2001 [27], but final
mortality rates for 2004 are now available [28]. For the
non-Hispanic white population, the age-adjusted rates are
5–6% lower than 2001. This corresponds to approximately
six extra months of life expectancy at age 50 years and
would have the effect of slightly increasing estimated 10-
year fracture risk in the older age groups.
Effect of revised assumptions for US-FRAX
The results of these revisions are summarized in Table 6,
which compares the current rates used in US-FRAX (based
on the sum of the four individual fracture types from
Olmsted County) to the newly derived four-fracture rates
based on the steps described above. The revised base annual
four-fracture rates are lower, and this should result in lower
US-FRAX 10-year four-fracture probability estimates. In-
deed, an average one-third reduction in four-fracture risk can
be expected in both women and men of all ages.
This revision of the US-FRAX incidence rates should
also mean that the absolute likelihood of four fractures for
US non-Hispanic white women will be closer to the
percentages obtained using FRAX® for European countries.
This was evaluated by comparing the four-fracture/hip
fracture ratios (for 10-year probability) from these countries
to the ratio of annual risk of these categories of fractures in
the proposed revision. Thus, Table 6 also shows the 10-year
four-fracture/hip fracture ratio for different ages calculated
from FRAX® online tables for a woman with body mass
index (BMI) of 25, without clinical risk factors, and with no
BMD value. The ratios across Europe are quite similar,
while the US ratios based on the October 2008 US-FRAX
tool are considerably higher. Judging from our revised
annual four-fracture and hip fracture incidence rates, it is
likely that the revised US-FRAX will provide results more
consistent with those of other countries.
Discussion
Since FRAX® was adapted for application in the USA
some years ago, newer and more robust fracture incidence
and mortality rates have become available. In particular, we
feel it highly advantageous to use recent hip fracture
incidence rates, which have the further advantage of being
based on more robust national data. These rates are lower
than those used previously in the US-FRAX, in part
reflecting ongoing secular trends in hip fracture occurrence.
Likewise, life expectancy is improving in this population as
documented in the updated mortality rates described. In lieu
of unequivocal data on vertebral fracture, we indirectly
estimated symptomatic vertebral fractures. Although it
would be preferable to have direct documentation of age-
and sex-specific incidence rates for the first of any one of
the four major osteoporotic fractures, this was not possible.
Instead, we explored the potential overlap of each of the
four major osteoporotic fractures using the new individual
rates of the four fracture types from our current analyses.
Our overlap analyses should be considered theoretical
exercises since FRAX® will apply its own Malmo-based
Table 6 Comparison of ratios of 10-year 4 fracture probability to 10-year hip fracture probability alone obtained from current FRAX® (available
on web site, January 2009)
Country Age, years
50 55 60 65 70 75 80
Estimates from FRAX®
a (10-year risk)
US current
b 16 13 11 11 6.2 4.2 3.5
Sweden 11 9.0 6.3 4.8 3.3 2.4 2.1
UK 18 12 8.6 6.6 4.8 3.1 2.4
Italy 16 9.0 6.7 5.1 3.3 2.4 2.1
France 12 9.3 6.6 5.1 3.5 2.5 2.3
Spain 14 10 6.0 4.6 3.5 2.5 2.3
Based on proposed revision to US incidence rates (annual)
US revised 14 12 10 5.9 4.4 2.4 1.9
The table also compares the current US ratios with estimates of ratios that might be expected based on revised annual US incidence rates
aFrom FRAX® tables for white women, without BMD, BMI=25, and no risk factors
bCalculated from the October 2008 version of US FRAX, for white women, without BMD, BMI=25, and no risk factors
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March 2, 2009, personal communication).
Currently, FRAX® uses race/ethnicity offsets relative to
non-Hispanic whites to estimate fracture probabilities
among US minorities. Our current analyses deal with non-
Hispanic whites only because fracture data available to us
on non-whites were less precise and less accurate. It would
be desirable and may be possible in the future to derive
more accurate racial offsets or to directly estimate risk in
non-whites, not only for hip fractures but also for the other
major osteoporotic fractures.
The implications of these incidence rate revisions will
need to be considered in several respects. Among younger
persons (below age 65 years), 10-year hip fracture
probability results will decline and could be up to 40%
lower than those produced by the current US-FRAX.
However, the decline in risk among younger subjects is
applied to a low starting hip fracture probability. Among
the oldest men and women, the revisions could work in the
opposite direction, increasing their hip fracture estimates
because annual base fracture rates are either unchanged or
increased while there would be declining competition from
death. The proposed changes in the major osteoporotic
fracture rates will systematically lower the 10-year likeli-
hood across all age groups. A more precise estimate of the
impact of these revisions on 10-year fracture probability
scores will be available once these revised annual rates
have been incorporated into US-FRAX.
For those with osteopenia, the NOF guide recommends
that treatment should be considered if the 10-year proba-
bility of hip fracture is 3% or more or if the major
osteoporotic fracture probability is 20% or more [19].
These thresholds were derived from a published cost-
effectiveness analysis [35]. The pending changes in US-
FRAX will likely alter the proportions of men and women
considered eligible for treatment [27]. However, we do not
anticipate that the proposed revisions will affect the size of
the treatment-eligible pool to a great extent for several
reasons. First, the segment of the population expected to
show the greatest decline in 10-year hip fracture probabil-
ities, young men and women, was already at very low
average risk and far below the NOF treatment threshold.
Nonetheless, some high-risk individuals in this group will
undoubtedly fall below the threshold as a result of this
change. Second, the majority of elderly men and women
will be eligible for treatment based on other criteria (e.g.,
hip or vertebral fracture or T-score at or below −2.5) [36].
Finally, if proposed changes lower the 10-year likelihood of
a major osteoporotic fracture in all age groups and move
significant numbers of people below the NOF 20%
threshold, the impact on overall osteoporosis treatment
eligibility is expected to be modest because an important
driver of treatment eligibility by US-FRAX is the 10-year
hip fracture probability [27]. In summary, we do not expect
upcoming changes in US-FRAX to dramatically affect the
number of individuals who are eligible for treatment.
Nonetheless, it will be important to examine the issue in a
more quantitative way. After the proposed changes are
incorporated into US-FRAX, this will be done in the form
of an updated cost-effectiveness analysis and a re-
assessment of the proportions of the population who would
be eligible for treatment.
FRAX® is a dynamic tool and one that can be expected
to undergo further updates and modifications in the future.
Although this may cause discontinuity in the management
of some individual patients, periodic revision will be
necessary in order to predict future risk accurately in the
context of expected ongoing changes in the US fracture
incidence and mortality rates.
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